

AMENDMENTS TO THE SPECIFICATION

Please replace the paragraph beginning on page 73, line 16 and ending on line 31 with the following amended paragraph:

To confirm earlier findings that vimentin can be found in the Golgi and ER ^{8,14}, immunohistochemical analysis was performed using antibodies to vimentin and ER or Golgi markers. These specific markers detected co-localization between vimentin and the ER (Figure 2 a-c), as well as between vimentin and the Golgi (Figure 2 d-f). In order to better address the issue of co-localization, consecutive optical section images were captured along the z-axis of the 12 day MDM preparation (Figure 2 g). As shown in the figure, this method clearly demonstrated the co-localization of vimentin with the Golgi. This confirms that the co-localization does not result from the presence of vimentin above or below the Golgi body, but in it. When proteins fractionated from supernatants of the 12 day MDM were analyzed by microcapillary mass spectrometry (see Table 1 (SEQ ID NO:1)) and by Western blot analysis with a specific anti-vimentin monoclonal antibody (Figure 2h), vimentin was readily identified. Full-length vimentin is set forth as SEQ ID NO:1 while amino acid sequence fragments are set forth as SEQ ID NOS:2-8. In order to confirm that vimentin was being actively secreted through the Golgi apparatus, the ability of the Golgi blocker monensin and the glycosylation blocker tunicamycin to inhibit the apparent secretion of vimentin from MDM was tested. Monensin and tunicamycin eliminate secretion of vimentin from the mature MDM as measured by Western blot (Figure 2h).

Please insert the attached Sequence Listing into the specification after the abstract.